Arthur Burghes, PhD, Appointed Chief Research Officer of the Gene Therapy Institute

The Gene Therapy Institute is pleased to announce the appointment of Arthur Burghes, PhD, as its new Chief Research Officer. An internationally recognized medical research scientist, Dr. Burghes brings four decades of groundbreaking research in the molecular genetics and biochemistry of neuromuscular disorders. In this role, Dr. Burghes will oversee the Institute's research strategy, foster interdisciplinary collaborations, and drive innovation in gene therapy research. 

Dr. Burghes is renowned for his pioneering work in spinal muscular atrophy (SMA). His research has moved the field through from gene discovery to tangible changes in the diagnosis and management of SMA, prolonging survival, improving motor functions and converting debilitating muscle weakness diseases to ones that ultimately can be cured. 

As Chief Research Officer, Dr. Burghes will lead key initiatives to support faculty development, optimize core research resources and advance strategic research programs in alignment with the GTI's mission. His leadership will be instrumental in expanding funding opportunities and strengthening the Institute's position as a leader in gene therapy research. With his extensive experience and strong commitment to scientific excellence, Dr. Burghes' appointment marks an exciting step forward for the Gene Therapy Institute. 

For more information, please visit: https://gti.osu.edu/about-us.